Drug Trial Radar · NCT04203342
A Therapeutic Equivalence Study of Ketoconazole Cream 2%
Last checked: Nov 20, 2026Latest source record: Aug 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
682
Actual
Start
Dec 11, 2019
Primary completion
May 28, 2020
Study completion Jul 13, 2020
Sponsor
- Lead sponsor
- Douglas Pharmaceuticals America LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Novum Pharmaceutical Research Services; ACM Global Laboratories
- First posted
- Dec 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.
Conditions
- Tinea Pedis
Interventions
Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)Drug
Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)Drug
Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)Drug
Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Therapeutic cure of tinea pedisTime frame: 2 weeks post-treatment (Day 56)
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Moore Clinical Research
Brandon, Florida
Moore Clinical Reseach
Tampa, Florida
FXM Research International
Belize City, Belize
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.